---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-040796"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:23:20.897664+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics raises ~$23M in registered direct offering with Perceptive, Nantahala, Balyasny

## Summary
- Purchase agreement with affiliates of Perceptive, Nantahala, and Balyasny for 3.83M shares and 7.18M pre-funded warrants at $2.09/$2.0899.
- Gross proceeds ~$23M; net proceeds to advance LCA5 and BEST-1 gene therapy programs and for working capital.
- Pre-funded warrants exercisable at $0.0001/share, subject to 4.99%/9.99% beneficial ownership limitation.
- Closing expected November 7, 2025; no placement agent or underwriting discounts.
- Offering registered on Form S-3; customary closing conditions remain.

## SEC filing metadata
- accession: 0001140361-25-040796
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125040796/0001140361-25-040796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125040796/ny20058362x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-040796
- JSON: https://secwatch.observer/filing/0001140361-25-040796.json
- Plain text: https://secwatch.observer/filing/0001140361-25-040796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.